News
Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...
Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...
Pfizer's revenue grew 7.1% to ₹604 crore from ₹563 crore, while EBITDA increased 18.1% to ₹209.7 crore from ₹177.6 crore in ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...
Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...
Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Pfizer launches PCV20 for adults in India to offer broad protection against pneumococcal disease: Our Bureau, Mumbai Wednesday, August 13, 2025, 15:45 Hrs [IST] Pfizer has announc ...
Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback